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Abstract
Background: ATP-regulated potassium channels (KATP) regulate pulmonary vascular tone and are involved in hypoxic
pulmonary vasoconstriction (HPV). In patients with inflammation like sepsis or ARDS, HPV is impaired, resulting in a
ventilation-perfusion mismatch and hypoxia. Since increase of vascular KATP channel Kir6.1 has been reported in
animal models of endotoxemia, we studied the expression and physiological effects of Kir6.1 in murine endotoxemic
lungs. We hypothesized that inhibition of overexpressed Kir6.1 increases HPV in endotoxemia.
Methods: Mice (C57BL/6; n = 55) with (n = 27) and without (n = 28) endotoxemia (35 mg/kg LPS i.p. for 18 h) were
analyzed for Kir6.1 gene as well as protein expression and HPV was examined in isolated perfused mouse lungs with
and without selective inhibition of Kir6.1 with PNU-37883A. Pulmonary artery pressure (PAP) and pressure-flow curves
during normoxic (FiO2 0.21) and hypoxic (FiO2 0.01) ventilation were obtained. HPV was quantified as the increase in
perfusion pressure in response to hypoxic ventilation in mmHg of baseline perfusion pressure (ΔPAP) in the presence
and absence of PNU-37883A.
Results: Endotoxemia increases pulmonary Kir6.1 gene (+ 2.8 ± 0.3-fold) and protein expression (+ 2.1 ± 0.3-fold).
Hypoxia increases HPV in lungs of control animals, while endotoxemia decreases HPV (ΔPAP control: 9.2 ± 0.
9 mmHg vs. LPS: 3.0 ± 0.7 mmHg, p < 0.05, means ± SEM). Inhibition of Kir6.1 with 1 μM PNU-37883A increases HPV in
endotoxemia, while not increasing HPV in controls (ΔPAP PNU control: 9.3 ± 0.7 mmHg vs. PNU LPS: 8.3 ± 0.9 mmHg,
p < 0.05, means ± SEM).
Conclusion: Endotoxemia increases pulmonary Kir6.1 gene and protein expression. Inhibition of Kir6.1 augments HPV
in murine endotoxemic lungs.
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Background
Hypoxic pulmonary vasoconstriction (HPV) is a physio-
logical reflex, reducing intrapulmonary shunt. It is
impaired in patients with sepsis or acute respiratory
distress syndrome (ARDS), resulting in a ventilation-
perfusion mismatch and systemic hypoxia. Reduced
HPV is not only restricted to critical ill humans but can
also be observed in several animal models of endotoxemia
[1–3]. Inflammatory mediators including prostaglandins,
thromboxanes, platelet-activating factor, leukotrienes, or
nitric oxide (NO) modulate HPV during lung inflamma-
tion [4]. Voltage gated potassium channels have been
shown to be one of the key regulators of HPV [5], but in
candidates like Kv1.5, Kv2.1 or Kv3.1, no alteration in ex-
pression levels in endotoxemia was found [3], despite un-
specific inhibition with 4-AP augments HPV. In contrast,
ATP sensitive K-channels (KATP) were demonstrated to
be increased in endotoxemia [6]. They are also involved in
regulation of pulmonary vascular tone and HPV in various
organisms, including mice, rats and pigs [7, 8]. Inhibition
of KATP channels has been shown to increase pulmonary
artery resistance [8].
The K-channel Kir6.1 (potassium inwardly-rectifying
channel, subfamily J, member 8) is encoded by the gene
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kcnj8. The channel is built by an octameric protein com-
plex consisting four pore-forming Kir6.1 units sur-
rounded by four sulfonylurea receptor subunits (SURs).
These SURs present binding sites for inhibitors like glib-
enclamid or PNU-99963, while the pore forming units
can be blocked by barium chloride or the vascular se-
lective KATP channel inhibitor, PNU-37883A [6, 9].
Expression of the KATP-channel Kir6.1 has been
shown in smooth muscle cells of pulmonary arteries, the
mouse aorta, rat mesenteric arteries, cerebral and coron-
ary arteries as well as urethral myocytes [10, 11].
Furthermore, KATP-channels have been described in rat
and bovine pulmonary vascular endothelial cells as well
as human pulmonary artery smooth muscle cells [12, 13].
Activation of KATP-channels increases efflux of K+,
resulting in increased closure of Ca2+ channels, de-
creased Ca2+-influx and reduced intracellular Ca2+,
which in turn leads to smooth muscle relaxation. In
endotoxemia, Kir6.1 has been shown to be up-
regulated in mouse aortic smooth muscle cells and at-
tributed to systemic hypotension [11].
We report that Kir6.1 expression was induced in endo-
toxemic mouse lungs on mRNA as well as protein level.
Immunohistochemistry showed a Kir6.1 immunoreactive
protein in pulmonary mouse veins and arteries. Selective
inhibition of Kir6.1 resulted in augmented HPV in iso-
lated perfused endotoxemic mouse lungs.
Methods
A total of 55 adult male C57BL/6 mice (Charles River
GmbH, Sulzfeld, Germany) with 8–10 weeks of age and
23.0 ± 0.2 g body weight (bw) were studied.
Experimental groups
Mice received an intraperitoneal (i.p.) injection of endo-
toxin (LPS; E.coli 0111:B4, 35 mg/kg bw; Sigma Chemical
Co., St. Louis, MO) in LPS groups (n = 7 per group) or
normal saline (controls, n = 8 per group) 18 h before iso-
lated lung perfusion experiments. Animals showed leth-
argy, piloerection, and diarrhea 18 h after LPS injection,
mortality rate was approximately 10%. For lung perfusion,
PNU-37883A (Sigma Chemical) was dissolved in ethanol
and added to give a final concentration in the perfus-
ate of 0 or 1 μM PNU-37883A in the respective
groups. The ethanol concentration used in the perfus-
ates was 0.5 mg/dl.
Isolated, perfused, and ventilated mouse lung model
Mice were sacrificed by an i.p. injection of pentobarbital
sodium (200 mg/kg body weight) (Merial, Hallbergmoos,
Germany) and lungs were explanted and buffer perfused
as previously described [3]. Perfusate flow was adjusted
using an in-line flow probe and flowmeter (Transonic
Systems, Ithaca, NY). The perfusate used was Hanks’
balanced salt solution (Life Technologies, Paisley, Scotland),
with bovine serum albumin (5%; Serva, Heidelberg,
Germany) and dextran (5%; Sigma-Aldrich Chemie,
Deisenhofen, Germany) added to prevent pulmonary
edema [3]. Indomethacin (30 mM; Sigma-Aldrich) and
1 mM of the nonselective nitric oxide synthase inhibitor L-
NAME were added to the perfusate to inhibit endogenous
prostaglandin synthesis and nitric oxide synthesis respect-
ively. PNU-37883A was added to the perfusate to give a
final concentration of 0 or 1 μM and stirred before lung
perfusion. Sodium bicarbonate was added to adjust the per-
fusate pH (7.34–7.43). Lungs were included in this study if
they had a homogenous white appearance without signs of
hemostasis or atelectasis and showed a stable perfusion
pressure less than 10 mmHg during the second 5 min of an
initial 10 min baseline perfusion period. Using these two
criteria, approximately 10% of lung preparations from each
group were discarded before study. Pulmonary artery pres-
sure (PAP) and left atrial pressure were measured via
saline-filled membrane pressure transducers connected to a
side port of the inflow and outflow cannula. Pressure trans-
ducers were connected to a biomedical amplifier, and data
were recorded at 150 Hz on a personal computer using an
analog-to-digital interface with a data acquisition system
(DI-220; Dataq Instruments, Akron, OH). The system was
calibrated before each experiment. HPV responsiveness
(ΔPAP) was quantified as the difference between basal pul-
monary arterial pressure (PAP) and PAP at the end of six
minute ventilation at FiO2 of 0.01.
Pulmonary vascular pressure-flow relationships were
obtained during normoxia and hypoxia. After a 10 min
equilibration period with normoxic ventilation (FiO2 =
0.21) and a perfusate flow of 50 ml*kg-1*min-1, flow was
set to 25, 50, 75, and 100 ml*kg-1*min-1 in a random-
ized fashion for 30 s each and the corresponding PAP
recorded. Then, ventilation was switched to hypoxic gas
(FiO2 = 0.01, perfusate flow 50 ml*kg-1*min-1) for meas-
urement of ΔPAP and a second pressure-flow relation-
ship was recorded in the same manner at the end of a
six minute ventilation at FiO2 of 0.01.
Pulmonary vascular pressure-flow relationships were
analyzed using a linear distensible vessel model as de-
scribed before [15]. Briefly, this model describes the vas-
cular pressure-flow characteristic using two parameters:
RLIN is interpreted as mean parallel resistance extra-
alveolar, non-collapsible pulmonary vessels and PZF as
mean critical closing pressure, representing a mean pres-
sure value below a pressure that would not result in a
flow in the pulmonary vessels.
Lung wet /dry weight ratio
At the end of the experiments, both lungs of the studied
animals, excluding their hilar structures, were excised
and immediately weighed. Thereafter, lungs were dried
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in an oven at 100 °C overnight and then re-weighted.
Lung wet/dry weight ratios were calculated by divid-
ing the wet weight by the dry weight as described
previously [16].
Semi-quantitative RT-PCR
Additional animals (n = 18) were used for isolation of
lung tissue for RNA and protein analysis. After 18 h of
LPS exposure (LPS; E.coli 0111:B4, 35 mg/kg bw i.p.;
Sigma Chemical Co., St. Louis, MO), mice were sacri-
ficed with a lethal i.p. injection of pentobarbital sodium
(200 mg/kg bw, three independent experiments with n =
3 each). Saline injected mice served as controls (also
three independent experiments with n = 3 each). Lungs
were exposed via median sternotomy and heparin (10 U)
was injected into the right ventricle. Lungs were per-
fused with iced physiological saline for one minute at
50 ml/kg-1/min-1 flow, dissected (excluding hilar struc-
tures), quick-frozen, and stored at − 80 °C.
RNA was isolated from mouse lungs using the RNeasy
Mini Kit (Qiagen) and cDNA was generated with
iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories,
Herkules, USA). Semi-quantitative PCR was carried out
on a MyiQ Single-Color Real-Time PCR detection system
(Bio-Rad Laboratories, Herkules, USA), using specific
primers for Kir6.1 (FP: GGCACACAAGAACATCCGA
GAG, RP: TGCAGAGGAAGGACATGGTGA) and 18S
(FP: TCAAGAACGAAAGTCGGAGG, RP: GGACATC
TAAGGGCATCAC). Postamplification dissociation curves
were performed to verify the presence of a single amplifica-
tion product in the absence of DNA contamination.
Changes in gene expression were determined using the
ΔΔCt method with normalization of 18S ribosomal RNA.
Immunoblotting
Western blots were performed to assess protein levels of
Kir6.1 and GAPDH. In brief, mouse lungs with and
without 18 h endotoxemia (three independent experi-
ments with n = 3 each) were homogenized at 4 °C in
PBS with 5 mM EGTA and protease inhibitor mix
(Roche Diagnostics GmbH, Germany) and centrifuged at
10,000 g and 4 °C for 10 min. Supernatant protein was
subjected to electrophoresis, transferred to a PVDF
membrane, blocked for 1 h at room temperature with
i-Block 0,5% and probed with anti-Kir6.1 (1:500,
Alomone, Jerusalem, Israel) and anti-GAPDH (1:10,000,
Millipore, Darmstadt, Germany) overnight at 4 °C. For
negative control, 1 μg of purified Kir6.1 control peptide
antigen (Alomone) was preincubated with 1 μg of anti-
body for one hour at room temperature and then incu-
bated with the membrane overnight at 4 °C. The PVDF
membranes were then incubated with corresponding
secondary antibodies (1:10,000 IRDye 680 and 800, LI-COR
Biotechnology, Lincoln, USA). Proteins were visualized with
a LI-COR infrared imager (Odyssey, LI-COR Biotechnol-
ogy), quantitative densitometric analysis was performed by
applying Odyssey version 1.2 infrared imaging software and
signals were normalized to GAPDH. Coincubation with the
Kir6.1 control peptide antigen faded away the Kir6.1 immu-
noreactive band at a size of 50 kDa.
Immunoenzyme staining
Lungs of mice with (n = 4) and without (n = 4) 18 h
of endotoxemia were fixed in paraformaldehyde.
Immunoenzyme stainings were performed on 2 μm
paraffin-embedded sections using standard avidin-biotin
anti-alkaline phosphatase technique (Vector Laboratories,
Burlingame, CA) according to the manufacturer’s instruc-
tions. Tris-buffered saline supplemented with 0.2% bovine
serum albumin (Biotrend, Cologne, Germany) was used as
buffer. Primary antibody dilutions of polyclonal rabbit
anti-Kir6.1, 1/50 (Alomone) and an isotype- and concen-
tration-matched rabbit control Ig (Dianova, Hamburg,
Germany) were prepared in this buffer and incubated
for 1 h at room temperature. A biotinylated donkey
anti-rabbit IgG Ab, 1/100 (Jackson ImmunoResearch,
Newmarket, UK), was used as a secondary reagent
(30 min at room temperature). Naphthol AS-
biphosphate (Sigma) with New-fuchsin (Merck,
Darmstadt, Germany) was used as the substrate for
alkaline phosphatase.
Statistical analysis
Data are reported as mean ± SEM. After approving the
assumption of normality and equal variance across
groups, differences were assessed using ANOVA
followed by an appropriate post hoc comparison test.
When significant differences were detected by ANOVA,
a post hoc least difference test for planned comparisons
was used (SPSS 24, IBM, Armonk, USA). Statistical sig-
nificance was assumed at a p value of less than 0.05.
Results
Endotoxemia increases pulmonary Kir6.1 gene expression
Mice exposed to 35 mg/kg LPS i.p. showed an increase
of Kir6.1 gene expression in total lung tissue extracts
(2.8 ± 0.3-fold, n = 9, p < 0.05) (Fig. 1) after 18 h when
compared to normal saline treated controls. These re-
sults suggest that endotoxemia increases RNA expres-
sion of the ATP-dependent potassium channel Kir6.1.
Endotoxemia increases Kir6.1 protein expression in the lung
To test whether up-regulation of Kir6.1 gene expres-
sion results also in increased protein expression, tis-
sue of mouse lungs was extracted after 18 h of
endotoxemia, saline injected animals served as con-
trols. Kir6.1 immunoreactive protein was increased in
whole lung extracts (2.1 ± 0.3-fold, n = 9, p < 0.05,
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mean ± SEM, Fig. 2). These results confirm that endo-
toxin challenge provokes an induction of Kir6.1 pro-
tein expression.
Kir6.1 expression is located pulmonary vessels
To evaluate location of Kir6.1 protein expression, lungs
of mice (n = 4) with and without 18 h of endotoxemia
where fixed in paraformaldehyde, paraffin-embedded
and stained with Kir6.1 specific antibodies (Fig. 3).
Kir6.1 positive staining was found in the wall of small
pulmonary arteries and veins. Region of interest of ma-
genta positive area (equals Kir6.1 positive staining) was
0.41 ± 0.29% in controls vs. LPS 0.60 ± 0.29% (normal-
ized on 1 control: 1.0 ± 0.29 vs. LPS 1.48 ± 0.51; p = 0.03,
mean ± SEM). These results show that Kir6.1 expression
is attributable to pulmonary vessels.
Pulmonary vascular response to hypoxic ventilation after
lipopolysaccharide challenge
Hypoxic ventilation of lungs of control mice caused
an HPV response (ΔPAP: + 9.2 ± 0.9 mmHg, Fig. 4).
Accordingly, the pulmonary vascular P-Q relationship
was shifted to higher pressures at respective flows
(Fig. 5a and b). These results demonstrate that venti-
lation of an isolated perfused mouse lung with hyp-
oxic gas increases PAP.
Baseline perfusion pressure under normoxic ventila-
tion did not differ between LPS-pretreated and un-
treated mice (control 7.1 ± 0.3 mmHg vs. LPS 7.4 ±
0.3 mmHg, Figs. 4 and 5a). In lungs of control mice,
ventilation with hypoxic gas mixture (FiO2 of 0.01) was
associated with an increase of pulmonary pressure (+
9.2 ± 0.9 mmHg), whereas development of HPV was at-
tenuated in mice with endotoxemia (+ 3.0 ± 0.7 mmHg)
after 6 min of hypoxic ventilation (Fig. 4).
Taken together, this data shows that hypoxia induces
HPV in lungs of control mice and endotoxemia attenu-
ates HPV.
Effects of PNU-37883A on pulmonary vascular tone and
HPV after lipopolysaccharide challenge
To determine whether pharmacological inhibition of
Kir6.1 would enhance HPV after exposure to LPS,
Fig. 1 Endotoxemia increases Kir6.1 gene expression in mouse lungs.
RNA was extracted from mice with and without endotoxemia (rRNA:
ribosomal RNA, representative QPCR, n = 3, means ± SEM, *P < 0.05 vs.
control, tested with ANOVA, for homogeneity and post hoc Tukey)
Fig. 2 Endotoxemia increases Kir6.1 protein expression in mouse lungs. Densitometric measurement of the Kir6.1 immunoreactive protein levels
is shown. (Representative immunoblot, n = 3, normalized to GAPDH, control normalized on 1, means ± SEM, *p < 0.05, tested with ANOVA, for
homogeneity and post hoc Tukey)
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lungs of mice with and without endotoxemia were
perfused with a buffer containing 1.0 μM PNU-
37883A. In untreated control mice, inhibition of
Kir6.1 by PNU-37883A at a dose of 1.0 μM did not
affect baseline PAP under normoxic conditions (con-
trol 7.1 ± 0.3 mmHg vs PNU 6.6 ± 0.3 mmHg).
Again, rise of PAP started within 2 min and reached
its maximum within 6 min. Perfusion with the
inhibitor PNU-37883A did not augment HPV in
control mice (Fig. 6).
In lungs of endotoxemic mice, inhibition of Kir6.1 by
PNU-37883A again did not affect baseline PAP (LPS 7.4
± 0.3 mmHg vs LPS/PNU 6.6 ± 0.8 mmHg). In contrast,
inhibition of Kir6.1 in lungs of endotoxemic mice
augmented HPV compared to lungs perfused without
inhibitor (Fig. 6).
Fig. 3 Kir6.1 immunoreactivity in lungs of control mice (left) and endotoxemic mice (right). Immunoenzyme stainings were performed on paraffin-
embedded sections using polyclonal rabbit anti-Kir6.1 1:50 (Alomone). Endothelial cells as well as smooth muscle cells of small pulmonary
vessels show positive staining in control as well as endotoxemic animals. RBC: red blood cells
Fig. 4 Endotoxemia decreases HPV in isolated perfused mouse lungs. Time course of pulmonary artery pressure at normoxic baseline (− 2 to 0 min)
and during hypoxic ventilation (1–6 min; hypoxia) in lungs isolated from LPS-pretreated (■) and untreated control mice (□) (n = 8 for controls, n = 7 for
LPS,*P < 0.05 vs. corresponding control, §P < 0.05 vs. control normoxia, mean ± SEM, tested with ANOVA, for homogeneity and post hoc Tukey)
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This shows that PNU-37883A does not alter HPV in
control but augments HPV in endotoxemic mice.
Analysis of pressure-flow curves
A four point pulmonary vascular P-Q curve was re-
corded in order to obtain more insight in the pulmonary
vascular response (Fig. 5a and b). Quantification in the
shape of P-Q curves was calculated according to the col-
lapsible vessel model of Permutt and Riley, as discussed
and published before [15]. In this ohmic-Starling resistor
model, changes in the shape of the P-Q curve are dis-
played in the slope (RLIN) and the extrapolated pressure
intercepts at zero flow (PZF) of a linear regression line
(Fig. 5c and d) [15–18].
Hypoxia induced an increase of Pzf (normoxia 4.0 ±
0.5, hypoxia 8.4 ± 0.6 mmHg) as well as RLIN (normoxia
62.5 ± 3.7 vs hypoxia 128.7 ± 7.5 mmHg*ml-1*kg-1*min-
1), thus increasing parallel resistance and critical closing
pressure (Fig. 5c and d). Endotoxemia did not alter Pzf
or RLIN in normoxic condition (Pzf normoxia LPS 4.2 ±
0.2 vs control 4.0 ± 0.5 mmHg and RLIN normoxia LPS
61.5 ± 3.7 vs 62.5 ± 3.7 mmHg*ml-1*kg-1*min-1) but re-
sulted in a decrease in Pzf and RLIN in hypoxia compared
to lungs from healthy animals (Pzf hypoxia LPS 5.4 ± 0.4
Fig. 5 Pressure-flow data obtained in isolated, perfused mouse lungs of untreated and LPS treated mice (a) (n = 8 for controls (□) and n = 7 for
LPS (■), trend lines). Lungs were isolated and perfused with a flow of 25, 50, 75, and 100 ml* kg − 1 * min − 1 during ventilation with a normoxic
(straight line) or hypoxic gas mixture (dashed line), respectively, and the resulting perfusion pressure (PAP) was recorded. b: Pressure-flow relationships
were obtained under perfusion with 1 μM PNU 37883A (n= 7 for PNU (○) and n= 7 for LPS/PNU (●), straight line normoxic gas, dashed line hypoxic gas.
c: Pzf increases upon hypoxic ventilation as well as RLIN (d). Perfusion with 1 μM PNU-37883A increased Pzf as well as RLIN during hypoxic ventilation (Fig. 5c
and d). (nx: normoxia, hx: hypoxia, *P< 0.05 vs. corresponding control, # vs. LPS, § vs corresponding normoxia; mean ± SEM, tested with ANOVA, for homo-
geneity and post hoc Tukey)
Fig. 6 Perfusion with PNU 37883A augments HPV in endotoxemic
mouse lungs. Effects of perfusion of lungs obtained from LPS-treated
(■) and untreated control (□) mice with 1 μM PNU-37883A upon hypoxia.
HPV is expressed as increase in percent of baseline perfusion pressure
(ΔPAP), (n= 8 for control and n= 7 for LPS, *P< 0.05 vs. control (w/o LPS
and w/o PNU 37883A), †P< 0.05 vs. lps. Mean ± SEM, tested with ANOVA,
for homogeneity and post hoc Tukey)
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vs control 8.4 ± 0.6 mmHg and RLIN hypoxia 99.4 ± 9.4
vs control 128.7 ± 7.5 mmHg*ml-1*kg-1*min-1). Perfu-
sion of control lungs with 1 μmol PNU-37883A did not
alter Pzf in normoxia as well as Pzf or RLIN in hypoxia,
while decreasing RLIN in normoxia (Pzf normoxia 4.4 ±
0.2 vs hypoxia 9.3 ± 0.5 mmHg and RLIN normoxia 49.3
± 3.1 vs hypoxia 119.5 ± 7.6 mmHg*ml-1*kg-1*min-1).
Perfusion of lungs from endotoxemic animals with
1 μmol PNU-37883A resulted in an increase of Pzf and
RLIN during hypoxia (LPS PNU hypoxia 7.2 ± 1.3 and
RLIN hypoxia 139.6 ± 7.8 mmHg*ml-1*kg-1*min-1).
Taken together analysis of pressure flow curves re-
sulted in an increase of Pzf (extrapolated pressure inter-
cepting at zero flow) and RLIN (slope of the PQ-curve) in
control as well as endotoxemic lungs during hypoxic
ventilation. Increase of Pzf and RLIN was reduced in
lungs of endotoxemic animals and RLIN was increased in
PNU-perfused endotoxemic lungs.
Lung wet/dry weight ratios revealed no significant dif-
ference between any of the studied groups.
(control 0.11 ± 0.04; LPS 0.11 ± 0.03, PNU 0.10 ± 0.01;
LPS/PNU 0.10 ± 0.01, mean ratio ± SEM).
Discussion
In the present investigation we studied the role of the
ATP dependent potassium channel Kir6.1 on HPV in an
endotoxemic mouse model. In lungs of endotoxemic
mice, Kir6.1 gene as well as protein expressions were in-
creased compared to controls. Immunohistochemical
staining showed Kir6.1 expression in small pulmonary
vessels. HPV was decreased in endotoxemic animals.
Selective inhibition of up-regulated Kir6.1 with PNU
37883A increased HPV in endotoxemic mouse lungs,
whereas HPV was unchanged in controls. Our results
suggest that LPS induced impaired HPV in mice can be
restored by inhibition of overexpressed Kir6.1.
Involvement of the ATP-dependent potassium channel
Kir6.1 in systemic circulation has been demonstrated in
numerous studies. Kir6.1 expression is up-regulated in
rats in LPS as well as in cecal ligation peritonitis (CLP)
models [11, 19, 20]. This is not only restricted to rats
but has been observed in mouse aortic smooth muscle
cells and guinea pigs [6, 21]. Thus, increased Kir6.1 ex-
pression is a specific pathophysiologic response to a
broad inflammatory stimulus at least in rodents. Endo-
toxin induced increase of Kir6.1 gene expression in rat
mesenteric arteries contributes to systemic hypotension
and can be restored by specific inhibition [6, 20].
Besides systemic circulation, Kir6.1 expression is also
increased in coronary arteries of endotoxemic mice,
leading to vasodilatation and maintaining myocardial
perfusion [11, 14]. In Kir6.1 knock out mice, coronary
blood flow during endotoxemia is decreased, with re-
duced cardiac function and augmented mortality [14].
These observations show the pivotal role of Kir6.1 in the
regulation of vascular tone, with vasodilatation and
hypotension in case of too much Kir6.1 activity and
vasospasm in case of total lack in Kir6.1 knock out
mice. Thus, inhibition of Kir6.1 increases HPV and by
this oxygenation, but complete suppression of Kir6.1
activity is likely to give rise to vasospasm with nega-
tive outcome.
Overactivity of Kir6.1 in vascular smooth muscle cells
was investigated in transgenic mouse models, showing
lower vascular contractility and blood pressure [22].
Besides overexpression of Ki6.1, activation of Kir6.1 in
endotoxemia was shown by elevated extracellular argin-
ine levels as well as phosphorylation via inhibited activity
of calcineurin [22–25]. Taken together, these studies
show an important role of Kir6.1 in vascular contractility
and an up-regulation of Kir6.1 expression in endotoxe-
mia in various animal models. This is in line with our
data of elevated pulmonary Kir6.1 RNA and protein
levels after LPS exposure.
LPS-induced systemic hypotension in rats was attrib-
uted to BKCa channel activity as well as KATP activity
[6, 26–28]. Although inhibition of KATP channels re-
stored hypotension in numerous animal models of sep-
sis, administration of the KATP inhibitor glibenclamid
in patients with septic shock showed no hemodynamic
benefit or increased pulmonary artery pressures but
lower blood glucose levels [28, 29]. This might be due to
the enteral route of administration of glibenclamid with
inadequate plasma concentrations or nonspecific inhib-
ition of SUR rather than specific inhibition of overex-
pressed pore forming Kir6.1 [6, 29].
Blocking pore-forming subunits of Kir6.1 with PNU-
37883A showed an inhibitory potency on native KATP
currents in pig urethral myocytes as well as in rat mes-
enteric arteries [29]. The concentration of PNU-37883A
used in our experiment is in line with an effective dose
of 1.1 μM PNU-37883A in isolated rat mesenteric arter-
ies [9] and pig urethral smooth muscle cells (0.7 μM)
[29]. Tomoda found a maximal vasoconstrictive effect of
3 μM PNU-37883A in levcromakalim (a Kir6.1 channel
opener) relaxed pig urethral smooth muscle cells but the
opposite effect with higher doses of PNU-37883A in Bay
K 8644 (a L-type calcium channel activator) treated
smooth muscle cells [29]. This was explained by voltage
dependent inhibition of KATP currents by PNU-37883A
[29]. Selective inhibition of Kir6.1 with 1 μM PNU-
37883A of denuded aortic rings 18 h after CLP de-
creased resting membrane potential in CLP but not in
control rings and increased basal tension in CLP but not
in control rings [20]. This shows a higher sensibility to
PNU-37883A suggesting an up-regulation of Kir6.1.
Since this was observed in denuded aortic rings, it indi-
cates that the effect is at least in part independent from
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the endothelium. This might be relevant since Kir6.1 is
also expressed in some endothelial cells.
Besides KATP channels, inhibitory effects of PNU-
37883A on voltage-dependent Ca2+ channels were ob-
served in a rat model of pinacidil (a cyanoguanidine
compound opening ATP-modulated potassium chan-
nels) induced hypotension with selectivity for Kir6.1 and
less affinity to pancreatic Kir6.2 [30–32]. The fact that
PNU-37883A did not augment further the magnitude of
HPV in control mice may be due to less activity of
Kir6.1 in controls compared to LPS treated animals or
an already maximal vasoconstrictor response by ventilat-
ing lungs with 1% oxygen.
Immunohistochemistry showed Kir6.1 immunoreactive
protein in small pulmonary vessels. Besides arteries,
veins can also contribute to total pulmonary vascular re-
sistance [33–35], an effect that is dependent on age and
species. In agreement to our data, Michelakis reported
expression of Kir6.1 gene expression in pulmonary arter-
ies and veins of rats [35]. Taken together, expression of
Kir6.1 is not restricted to systemic circulation but also
can be found in lung vessels.
LPS increased Kir6.1 expression may be mediated by
NFκB. It has been reported that NFκB regulates Kir6.1
expression and in turn expression of NFκB is dependent
on the nitric oxide pathway [19]. Involvement of the ni-
tric oxide pathway in endotoxemia is also supported by
studies restoring HPV through inhibition of inducible
nitric oxide synthetase (iNOS) [15] or soluble guanylate
cyclase (sGC) [36]. Induction of Kir6.1 expression via
sGC has also been reported in a guinea pig ileitis model,
when mesenteric lymphatic pumping was compromised
while iNOS and Kir6.1 gene expression were up-
regulated [21]. Inhibition of iNOS, sGC or Kir6.1 in iso-
lated, luminally perfused mesenteric lymphatic vessels
improved lymphatic pumping [21]. NFκB expression can
by down-regulated by CO in LPS stimulated mouse peri-
toneal macrophages [37]. Thus, restoration of HPV by
inhaled CO (iCO) in endotoxemic mice [38] might be
attributable to anti-inflammatory effects of iCO via
NFκB expression.
Taken together, induced Kir6.1 expression and activity
by increased NFκB expression (via nitric oxide and sGC)
is a possible pathway to reduce HPV in endotoxemia.
On cellular level, activated Kir6.1 might decrease HPV
via increased efflux of K+ and thereby decreased intra-
cellular Ca2+. Selective inhibition of overexpressed
Kir6.1 results in a decrease of K+ efflux which in turn in-
creases Ca2+-influx and smooth muscle cell contraction,
resulting in increased HPV. Voltage gated potassium
channels involved in HPV of non-endotoxemic animals
are Kv1.5 and Kv2.1 [39]. A number of tested voltage
gated potassium channels (Kv1.5, Kv2.1, Kv3.1) were un-
changed on RNA level in lungs of endotoxemic mice [3].
On the contrary, Kv1.2 was found to be less expressed in
endotoxemia [3]. Analysis of pressure-flow relationships
are in line with previous studies, with hypoxia-induced
increases in mean parallel ohmic resistance RLIN as well
as an increase of extrapolated closing pressure PZF in
controls [15]. These hypoxia-induced increases in RLIN
and PZF were reduced in endotoxemia compared to un-
treated mice as described before [15]. Perfusion with
PNU-37883A did not change normoxic PZF and showed
same patterns as controls during hypoxic ventilation. In
contrast, perfusion of endotoxemic mouse lungs with
PNU-37883A increased both, RLIN and PZF, thus antag-
onizing LPS induced decreased pulmonary vascular re-
sistance as well as selectively enhancing vasoconstrictor
response upon hypoxia. In a similar LPS mouse model
with in vivo measurements, reduced HPV was observed
in endotoxemia, resulting in a V/Q mismatch and sys-
temic hypoxia [35]. Due to the model of the isolated
perfused mouse lung, we were not able to measure
the parameter of systemic oxygenation. Instead, we
measured the total increase of pulmonary pressure
upon hypoxia.
Up-regulation of Kir6.1 gene expression in endotoxe-
mic mice is consistent with data from mouse smooth
muscle cells showing a transcription dependent up-
regulation after 20 h of LPS exposure [11]. Like Weiwei,
a LPS model of endotoxemia was used since it shows a
high reproducibility of systemic inflammation with less
variability compared to cecal ligation and puncture
models [39]. The model of the isolated perfused mouse
lung offers a possibility to study selective effects of pul-
monary vasoactive drugs and hypoxic stimuli without
interfering with other organs like the heart, which might
be affected by the studied drug by arrhythmias or a
modified cardiac output [3]. Since the model excludes
systemic circulation, parameter like systemic oxygen-
ation cannot be measured. In vivo measurements in
mice showed a decrease of systemic oxygenation and a
V/Q –mismatch in a similar LPS i.p. model also used in
this study [40].
In order to exclude acute cyclooxygenase dependent
mechanisms to interfere with HPV, the cyclooxygenase
inhibitor indomethacin was added to the perfusate.
Metabolism of arachidonic acids by cyclooxygenases in
the lung produces diverse prostaglandins, regulating vas-
cular tone. Loss of HPV as well as systemic vasodilatory
effects can be attributed to these prostaglandins. The cy-
clooxygenase inhibitor indomethacin was shown to in-
crease HPV in a canine model of lung injury and to
reduce HPV in isolated pulmonary sheep veins but had
no effect in a murine model of HPV [41–43].
Nitric oxide produced by NOS (nitric oxide synthetase)
regulates pulmonary vascular tone. Since we wanted to
exclude acute NOS dependent effects in our model,
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perfusion buffer contained L-NAME. Inhibition of NOS
by L-NAME augments HPV dose-dependent in blood
perfused isolated rat lungs, whereas it has no effect on
buffer perfused rat lungs [44, 45]. There was no change by
L-NAME in baseline perfusion pressure in buffer perfused
isolated perfused rabbit or mouse lungs [46, 47].
Lung wet/dry weight ratios were comparable between
groups, suggesting the absence of pulmonary edema.
This is in contrast to in vivo observations of endotoxe-
mic mice, where lung edema was found to be iNOS-
dependent [48]. However, our data is in line with
previous studies of endotoxemic isolated perfused mouse
lungs, that used the same perfusate containing albumine
5% as well as dextran 5% [3, 15, 16]. Thus, the in vitro
model is able to compare effects of hypoxia or pharma-
cological inhibition from the same starting PAP in con-
trol and endotoxemic lungs but might display other
results than in vivo measurements of acute lung injury.
Another factor might be the type of LPS used, since in-
duction of iNOS expression can vary even with the LOT
number of [16].
Conclusion
The ATP sensitive K-channel Kir6.1 is overexpressed in
lungs of LPS treated mice on RNA as well as protein
level and can be inhibited by PNU-37883A, thereby aug-
menting HPV in endotoxemia but not in controls. Our
study suggests that selective inhibition of Kir6.1 might
represent a useful tool to enhance HPV in subjects with
endotoxemia and respiratory failure.
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